Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 235
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Am J Transplant ; 2024 Sep 07.
Artigo em Inglês | MEDLINE | ID: mdl-39245146

RESUMO

The American Transplant Congress (ATC) is the largest national transplant meeting in the United States jointly sponsored by the American Society of Transplantation and the American Society of Transplant Surgeons. The 2024 ATC was held in Philadelphia, Pennsylvania during which a number of peer-reviewed scientific abstracts were censored from the program by the Health Resources and Services Administration. These abstract presentations were redacted from the program for perceived conflict with current government policy effectively restricting dissemination of highly rated findings and discussion in a scientific forum. In this viewpoint, we describe the content of the abstracts that were withdrawn from the annual ATC meeting and the implications of this censorship by the Health Resources and Services Administration. We further consider the ramifications of this action for the prospective evaluation of government policy and the relationship of the contract agency with the transplant community in the context of ongoing discussions of modernizing the transplant system which has previously been critiqued for lack of transparency.

2.
Am J Transplant ; 2024 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-39306279

RESUMO

Time limits on organ viability from retrieval to implantation shape the US system for human organ transplantation. Preclinical research has demonstrated that emerging biopreservation technologies can prolong organ viability, perhaps indefinitely. These technologies could transform transplantation into a scheduled procedure without geographic or time constraints, permitting organ assessment and potential preconditioning of the recipients. However, the safety and efficacy of advanced biopreservation with prolonged storage of vascularized organs followed by reanimation will require new regulatory oversight, as clinicians and transplant centers are not trained in the engineering techniques involved or equipped to assess the manipulated organs. Although the Food and Drug Administration is best situated to provide that process oversight, the agency has until now declined to oversee organ quality and has excluded vascularized organs from the oversight framework of human cells, tissues, and cellular-based and tissue-based products. Integration of advanced biopreservation technologies will require new facilities for organ preservation, storage, and reanimation plus ethical guidance on immediate organ use versus preservation, national allocation, and governance of centralized organ banks. Realization of the long-term benefit of advanced biopreservation requires anticipation of the necessary legal and ethical oversight tools and that process should begin now.

3.
Bull World Health Organ ; 102(10): 707-714, 2024 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-39318889

RESUMO

In recent decades, considerable advances have been made in assuring the safety of blood transfusion and organ transplantation. However, with the increasing movement of medical products of human origin across international boundaries, there is a need to enhance global norms and governance. These products, which include blood, organs, tissues, cells, human milk and faecal microbiota, are today crucial for health care but they also pose unique risks due to their human origin, such as disease transmission and graft failure. Moreover, the demand for medical products of human origin often exceeds supply, leading to dependence on international supply chains, and emerging technologies like cell and gene therapy present further challenges because of their unproven efficacy and long-term risks. Current regulatory mechanisms, especially in low- and middle-income countries, are insufficient. The World Health Organization (WHO) has both the mandate and experience to lead the development of international quality and safety standards, consistent product nomenclature, and robust traceability and biovigilance systems. An international, multistakeholder approach is critical for addressing the complexities of how medical products of human origin are used globally and for ensuring their safety. This approach will require promoting uniform product descriptions, enhancing digital communication systems and leveraging existing resources to support countries in establishing regulations for these products. As illustrated by World Health Assembly resolution WHA77.4 on transplantation in 2024, WHO's ongoing efforts to ensure the safe, efficient and ethical use of medical products of human origin worldwide provide the opportunity to galvanize international cooperation on establishing norms.


Au cours des dernières décennies, des progrès considérables ont été réalisés pour assurer la sécurité des transfusions sanguines et des transplantations d'organes. Cependant, avec l'augmentation de la circulation de produits médicaux d'origine humaine par-delà les frontières internationales, il est impératif de renforcer la gouvernance et les normes mondiales. Ces produits, parmi lesquels figurent le sang, les organes, les tissus, les cellules, le lait maternel et le microbiote fécal, sont aujourd'hui essentiels pour les soins de santé. Mais ils comportent également des risques particuliers en raison de leur origine humaine, comme la transmission de maladies et le rejet de greffe. En outre, la demande en produits médicaux d'origine humaine dépasse souvent l'offre, ce qui engendre une dépendance vis-à-vis des chaînes d'approvisionnement internationales, tandis que des technologies émergentes telles que la thérapie cellulaire et génique posent de nouveaux défis en raison de leur efficacité non démontrée et des risques à long terme. Les mécanismes de réglementation actuels sont insuffisants, surtout dans les pays à revenu faible et intermédiaire. L'Organisation mondiale de la Santé (OMS) possède à la fois le mandat et l'expérience nécessaires pour mener le développement de normes internationales de qualité et de sécurité, d'une nomenclature cohérente des produits, ainsi que de systèmes de traçabilité et de biovigilance solides. Une approche internationale et multilatérale est cruciale pour gérer la complexité liée à l'utilisation de produits médicaux d'origine humaine dans le monde et garantir leur innocuité. Cette approche devra prévoir la mise en place de descriptions de produits uniformes, l'amélioration des systèmes de communication numériques et l'exploitation des ressources existantes afin d'aider les pays à définir des règles pour de tels produits. Comme l'illustre la résolution WHA77.4 de l'Assemblée mondiale de la Santé sur la transplantation, émise en 2024, les efforts constants de l'OMS visant à assurer la sécurité, l'efficacité et l'usage éthique des produits médicaux d'origine humaine à travers le monde représente l'occasion de stimuler la coopération internationale en matière d'établissement des normes.


En las últimas décadas, se han realizado avances considerables para garantizar la seguridad de las transfusiones de sangre y los trasplantes de órganos. Sin embargo, con el creciente movimiento de productos médicos de origen humano a través de las fronteras internacionales, es necesario reforzar las normas y la gobernanza mundiales. Estos productos, que incluyen sangre, órganos, tejidos, células, leche humana y microbiota fecal, son hoy cruciales para la asistencia sanitaria, pero también plantean riesgos únicos por su origen humano, como la transmisión de enfermedades y el fracaso de los injertos. Además, la demanda de productos médicos de origen humano suele ser superior a la oferta, lo que hace depender de las cadenas de suministro internacionales, y las tecnologías emergentes, como la terapia celular y genética, plantean nuevos desafíos debido a su eficacia no demostrada y a sus riesgos a largo plazo. Los mecanismos reguladores actuales, en especial en los países de ingresos bajos y medios, son insuficientes. La Organización Mundial de la Salud (OMS) tiene tanto el mandato como la experiencia para liderar el desarrollo de estándares internacionales de calidad y seguridad, nomenclatura coherente de productos y sistemas sólidos de trazabilidad y biovigilancia. Para responder a la complejidad del uso global de los productos médicos de origen humano y garantizar su seguridad, es fundamental un enfoque internacional que incluya a todas las partes interesadas. Este enfoque requerirá promover descripciones uniformes de los productos, reforzar los sistemas de comunicación digital y aprovechar los recursos existentes con el fin de ayudar a los países a establecer normativas para estos productos. Como se ilustra en la resolución WHA77.4 de la Asamblea Mundial de la Salud sobre trasplantes en 2024, los esfuerzos en curso de la OMS para asegurar el uso seguro, eficiente y ético de los productos médicos de origen humano en todo el mundo brindan la oportunidad de impulsar la cooperación internacional en el establecimiento de normas.


Assuntos
Organização Mundial da Saúde , Humanos , Saúde Global , Cooperação Internacional , Produtos Biológicos/normas
4.
Transpl Int ; 37: 12320, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38357216

RESUMO

The instant blood-mediated inflammatory response (IBMIR) causes islet loss and compromises diabetes outcomes after total pancreatectomy with islet autotransplant (TPIAT). We previously reported a possible benefit of etanercept in maintaining insulin secretion 3 months post-TPIAT. Here, we report 2-year diabetes outcomes and peri-operative inflammatory profiles from a randomized trial of etanercept and alpha-1 antitrypsin (A1AT) in TPIAT. We randomized 43 TPIAT recipients to A1AT (90 mg/kg IV x6 doses, n = 13), etanercept (50 mg then 25 mg SQ x 5 doses, n = 14), or standard care (n = 16). Inflammatory cytokines, serum A1AT and unmethylated insulin DNA were drawn multiple times in the perioperative period. Islet function was assessed 2 years after TPIAT with mixed meal tolerance test, intravenous glucose tolerance test and glucose-potentiated arginine induced insulin secretion. Cytokines, especially IL-6, IL-8, IL-10, and MCP-1, were elevated during and after TPIAT. However, only TNFα differed significantly between groups, with highest levels in the etanercept group (p = 0.027). A1AT increased after IAT in all groups (p < 0.001), suggesting endogenous upregulation. Unmethylated insulin DNA ratios (a marker of islet loss) and 2 years islet function testing were similar in the three groups. To conclude, we found no sustained benefit from administering etanercept or A1AT in the perioperative period.


Assuntos
Diabetes Mellitus , Transplante das Ilhotas Pancreáticas , Humanos , Etanercepte/uso terapêutico , Autoenxertos , Transplante Autólogo , Insulina , Inflamação , Citocinas , DNA , Pancreatectomia , Resultado do Tratamento
5.
HPB (Oxford) ; 26(5): 664-673, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38368218

RESUMO

BACKGROUND: Total pancreatectomy with islet autotransplant (TPIAT) can improve quality of life for individuals with pancreatitis but creates health risks including diabetes, exocrine insufficiency, altered intestinal anatomy and function, and asplenia. METHODS: We studied survival and causes of death for 693 patients who underwent TPIAT between 2001 and 2020, using the National Death Index with medical records to ascertain survival after TPIAT, causes of mortality, and risk factors for death. We used Kaplan Meier curves to examine overall survival, and Cox regression and competing-risks methods to determine pre-TPIAT factors associated with all-cause and cause-specific post-TPIAT mortality. RESULTS: Mean age at TPIAT was 33.6 years (SD = 15.1). Overall survival was 93.1% (95% CI 91.2, 95.1%) 5 years after surgery, 85.2% (95% CI 82.0, 88.6%) at 10 years, and 76.2% (95% CI 70.8, 82.3%) at 15 years. Fifty-three of 89 deaths were possibly related to TPIAT; causes included chronic gastrointestinal complications, malnutrition, diabetes, liver failure, and infection/sepsis. In multivariable models, younger age, longer disease duration, and more recent TPIAT were associated with lower mortality. CONCLUSIONS: For patients undergoing TPIAT to treat painful pancreatitis, careful long-term management of comorbidities introduced by TPIAT may reduce risk for common causes of mortality.


Assuntos
Causas de Morte , Transplante das Ilhotas Pancreáticas , Pancreatectomia , Humanos , Pancreatectomia/efeitos adversos , Pancreatectomia/mortalidade , Feminino , Masculino , Transplante das Ilhotas Pancreáticas/efeitos adversos , Adulto , Fatores de Risco , Pessoa de Meia-Idade , Transplante Autólogo , Adulto Jovem , Estudos Retrospectivos , Medição de Risco , Fatores de Tempo , Adolescente , Resultado do Tratamento , Pancreatite/mortalidade , Pancreatite/etiologia , Pancreatite Crônica/cirurgia , Pancreatite Crônica/mortalidade
6.
Pancreatology ; 23(1): 57-64, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36443174

RESUMO

BACKGROUND: In total pancreatectomy with islet auto-transplantation, successful diabetes outcomes are limited by islet loss from the instant blood mediated inflammatory response. We hypothesized that blockade of the inflammatory response with either etanercept or alpha-1-antitrypsin would improve islet function and insulin independence. METHODS: We randomized 43 participants to receive A1AT (90 mg/kg x 6 doses, n = 13), or etanercept (50 mg then 25 mg x 5 doses, n = 14), or standard care (n = 16), aiming to reduce detrimental effects of innate inflammation on early islet survival. Islet graft function was assessed using mixed meal tolerance testing, intravenous glucose tolerance testing, glucose-potentiated arginine-induced insulin secretion studies, HbA1c, and insulin dose 3 months and 1 year post-TPIAT. RESULTS: We observed the most robust acute insulin response (AIRglu) and acute C-peptide response to glucose (ACRglu) at 3 months after TPIAT in the etanercept-treated group (p ≤ 0.02), but no differences in other efficacy measures. The groups did not differ overall at 1 year but when adjusted by sex, there was a trend towards a sex-specific treatment effect in females (AIRglu p = 0.05, ACRglu p = 0.06), with insulin secretion measures highest in A1AT-treated females. CONCLUSION: Our randomized trial supports a potential role for etanercept in optimizing early islet engraftment but it is unclear whether this benefit is sustained. Further studies are needed to evaluate possible sex-specific responses to either treatment. CLINICAL TRIAL NOTATION: This study was performed under an Investigational New Drug Application (IND #119828) from the Food and Drug Administration and was registered on clinicaltrials.gov (NCT#02713997).


Assuntos
Diabetes Mellitus , Transplante das Ilhotas Pancreáticas , Pancreatite Crônica , Feminino , Humanos , Masculino , Diabetes Mellitus/cirurgia , Etanercepte/farmacologia , Etanercepte/uso terapêutico , Glucose , Insulina/uso terapêutico , Pancreatectomia , Pancreatite Crônica/cirurgia , Projetos Piloto , Transplante Autólogo , Resultado do Tratamento , Timalfasina
7.
Transpl Infect Dis ; 25(4): e14093, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-37432941

RESUMO

BACKGROUND: The HIV Organ Policy Equity (HOPE) act afforded transplantation of organs from donors who have HIV. Herein we compared the long-term outcomes of recipients with HIV by donor HIV testing status. METHODS: Using the Scientific Registry of Transplant Recipients, we identified all primary adult kidney transplant recipients who were HIV-positive between 1/1/16-12/31/21. Recipients were grouped into three cohorts according to the donor HIV status based on antibody (Ab) and nucleic acid testing (NAT): Donor Ab-/NAT- (n = 810), Donor Ab+ /NAT- (n = 98), and Donor Ab+/NAT+ (n = 90). We compared recipient and death-censored graft survival (DCGS) by donor HIV testing status using Kaplan-Meier curves and Cox proportional hazards regression, censored at 3 years posttransplant. Secondary outcomes were delayed graft function (DGF) and the following 1-year outcomes: acute rejection, re-hospitalization, and serum creatinine. RESULTS: In Kaplan-Meier analyses, patient survival and DCGS were similar by donor HIV status (log rank p = .667; log rank p = .388). DGF occurred more frequently in donors with HIV Ab-/NAT- testing compared with Ab+/NAT- or Ab+/NAT+ testing (38.0% vs. 28.6% vs. 26.7%, p = .028). Average dialysis time before transplant was twice as long for recipients who received organs from donors with Ab-/NAT- testing (p < .001). Acute rejection, re-hospitalization and serum creatinine at 12 months did not differ between the groups. CONCLUSIONS: Patient and allograft survival for recipients living with HIV remains comparable irrespective of donor HIV testing status. Utilizing kidneys from deceased donors with HIV Ab+/NAT- or Ab+/NAT+ testing shortens dialysis time prior to transplant.


Assuntos
Infecções por HIV , HIV , Adulto , Humanos , Estados Unidos/epidemiologia , Creatinina , Doadores de Tecidos , Rim , Sobrevivência de Enxerto , Rejeição de Enxerto/prevenção & controle
8.
Cryobiology ; 110: 1-7, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36640932

RESUMO

Transplantation has substituted dysfunctional organs with healthy organs from donors to significantly lower morbidity and mortality associated with end-stage organ disease. Since the advent of transplantation, the promise of functional replacement has attracted an exponential mismatch between organ supply and demand. Theoretical proposals to counter the increasing needs have either been to create a source through genetic engineering of porcine donors for xenotransplantation (with more potent immunosuppression protocols) or recreate one's organ in a pig using interspecies blastocyst complementation for exogenic organ transplantation (without immunosuppression). Another promising avenue has been organ banking through cryopreservation for transplantation. Although ice free preservation and acceptable early function following rewarming is critical for success in transplantation, the immunological response that predominantly defines short- and long-term graft survival has failed to captivate attention to date. It is well sorted that thermal and metabolic stress incurred at 4 °C during recovery and reperfusion of organs for clinical transplantation has varying impact on graft survival. Considering the magnitude of cellular imbalance and injury at sub-zero/ultralow temperatures in addition to the chemical toxicity of cryoprotective agents (CPA), it is essential to assess and address the immunological response associated following transplantation to maximize the success of cryopreservation.


Assuntos
Criopreservação , Rim , Animais , Suínos , Criopreservação/métodos , Transplante Heterólogo , Temperatura , Crioprotetores
9.
Am J Transplant ; 22(3): 853-864, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-34741800

RESUMO

Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. Median recipient CD4 was 287 cells/µL with 100% on antiretroviral therapy; 56% were hepatitis C virus (HCV)-seropositive, 13% HCV-viremic. Weighted 1-year survival was 83.3% versus 100.0% in D+ versus D- groups (p = .04). There were no differences in one-year graft survival (96.0% vs. 100.0%), rejection (10.8% vs. 18.2%), HIV breakthrough (8% vs. 10%), or SAEs (all p > .05). HIV D+/R+ had more opportunistic infections, infectious hospitalizations, and cancer. In this multicenter pilot study of HIV D+/R+ LT, patient and graft survival were better than historical cohorts, however, a potential increase in infections and cancer merits further investigation.


Assuntos
Infecções por HIV , Hepatite C , Transplante de Fígado , Seguimentos , Sobrevivência de Enxerto , Infecções por HIV/complicações , Humanos , Transplante de Fígado/efeitos adversos , Projetos Piloto , Estudos Prospectivos , Doadores de Tecidos
10.
Ann Surg ; 276(3): 441-449, 2022 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-35762611

RESUMO

OBJECTIVE: To determine if islet autotransplantation (IAT) independently improves the quality of life (QoL) in patients after total pancreatectomy and islet autotransplantation (TP-IAT). BACKGROUND: TP-IAT is increasingly being used for intractable chronic pancreatitis. However, the impact of IAT on long-term islet function and QoL is unclear. METHODS: TP-IAT patients at our center >1 year after TP-IAT with ≥1 Short Form-36 QoL measure were included. Patients were classified as insulin-independent or insulin-dependent, and as having islet graft function or failure by C-peptide. The associations of insulin use and islet graft function with QoL measures were analyzed by using a linear mixed model, accounting for time since transplant and within-person correlation. RESULTS: Among 817 islet autograft recipients, 564 patients [median (interquartile range) age: 34 (20, 45) years, 71% female] and 2161 total QoL surveys were included. QoL data were available for >5 years after TP-IAT for 42.7% and for >10 years for 17.3%. Insulin-independent patients exhibited higher QoL in 7 of 8 subscale domains and for Physical Component Summary and Mental Component Summary scores ( P <0.05 for all). Physical Component Summary was 2.91 (SE=0.57) higher in insulin-independent patients ( P <0.001). No differences in QoL were observed between those with and without graft function, but islet graft failure was rare (15% of patients). However, glycosylated hemoglobin was much higher with islet graft failure. CONCLUSIONS: QoL is significantly improved when insulin independence is present, and glycosylated hemoglobin is lower with a functioning islet graft. These data support offering IAT, rather than just performing total pancreatectomy and treating with exogenous insulin.


Assuntos
Transplante das Ilhotas Pancreáticas , Pancreatite Crônica , Adulto , Feminino , Hemoglobinas Glicadas , Humanos , Insulina , Masculino , Pancreatectomia , Pancreatite Crônica/complicações , Pancreatite Crônica/cirurgia , Qualidade de Vida , Transplante Autólogo , Resultado do Tratamento
11.
Pancreatology ; 22(1): 1-8, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34620552

RESUMO

BACKGROUND: Total pancreatectomy with islet autotransplantation (TPIAT) is a viable option for treating debilitating recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) in adults and children. No data is currently available regarding variation in approach to operation. METHODS: We evaluated surgical techniques, islet isolation and infusion approaches, and outcomes and complications, comparing children (n = 84) with adults (n = 195) enrolled between January 2017 and April 2020 by 11 centers in the United States in the Prospective Observational Study of TPIAT (POST), which was launched in 2017 to collect standard history and outcomes data from patients undergoing TPIAT for RAP or CP. RESULTS: Children more commonly underwent splenectomy (100% versus 91%, p = 0.002), pylorus preservation (93% versus 67%; p < 0.0001), Roux-en-Y duodenojejunostomy reconstruction (92% versus 35%; p < 0.0001), and enteral feeding tube placement (93% versus 63%; p < 0.0001). Median islet equivalents/kg transplanted was higher in children (4577; IQR 2816-6517) than adults (2909; IQR 1555-4479; p < 0.0001), with COBE purification less common in children (4% versus 15%; p = 0.0068). Median length of hospital stay was higher in children (15 days; IQR 14-22 versus 11 days; IQR 8-14; p < 0.0001), but 30-day readmissions were lower in children (13% versus 26%, p = 0.018). Rate of portal vein thrombosis was significantly lower in children than in adults (2% versus 10%, p = 0.028). There were no mortalities in the first 90 days post-TPIAT. CONCLUSIONS: Pancreatectomy techniques differ between children and adults, with islet yields higher in children. The rates of portal vein thrombosis and early readmission are lower in children.


Assuntos
Transplante das Ilhotas Pancreáticas , Laparoscopia , Pancreatectomia , Pancreatite Crônica/cirurgia , Doença Aguda , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Prospectivos , Transplante Autólogo , Resultado do Tratamento
12.
Transpl Infect Dis ; 24(1): e13720, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34455662

RESUMO

BACKGROUND: Clostridioides difficile infection (CDI) frequently complicates allogeneic hematopoietic stem cell (allo-HCT) and solid organ transplantation (SOT). METHODS: We retrospectively analyzed risk factors and outcomes of CDI occurring within 30 days of transplant. RESULTS: Between March 2010 and June 2015, 466 allo-HCT and 1454 SOT were performed. The CDI cumulative incidence (95% CI) was 10% (8-13) and 4% (3-5), following allo-HCT and SOT, respectively (p < .01), occurring at a median (range) 7.5 days (1-30) and 11 (1-30), respectively (p = .18). In multivariate analysis, fluoroquinolones use within 14 days pre-transplantation was a risk factor for CDI following allo-HCT (HR 4.06 [95% CI 1.31-12.63], p = .02), and thoracic organ(s) transplantation was a risk factor for CDI following SOT (HR 3.03 [95% CI 1.31-6.98]) for lung and 3.90 (1.58-9.63) for heart and heart/kidney transplant, p = .02. Compared with no-CDI patients, the length of stay (LOS) was prolonged in both allo-HCT (35 days [19-141] vs. 29 [13-164], p < .01) and SOT with CDI (16.5 [4-101] vs. 7 [0-159], p < .01), though not directly attributed to CDI. In allo-HCT, severe acute graft-versus-host disease (aGVHD) occurred more frequently in patients with CDI (33.3% vs. 15.8% without CDI, p = .01) and most aGVHD (87.5%) followed CDI. Non-relapse mortality or overall survival, not attributed to CDI, were also similar in both allo-HCT and SOT. CONCLUSIONS: Early post-transplant CDI is frequent, associated with fluoroquinolones use in allo-HCT and the transplanted organ in SOT, and is associated with longer LOS in both the groups without difference in survival but with increased aGVHD in allo-HCT.


Assuntos
Clostridioides difficile , Infecções por Clostridium , Transplante de Células-Tronco Hematopoéticas , Transplante de Órgãos , Infecções por Clostridium/epidemiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Células-Tronco Hematopoéticas , Humanos , Transplante de Órgãos/efeitos adversos , Estudos Retrospectivos , Transplantados
13.
Am J Transplant ; 21(10): 3411-3420, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-33754431

RESUMO

In this single-center, retrospective cohort study, we aimed to elucidate simple metabolic markers or surrogate indices of ß-cell function that best predict long-term insulin independence and goal glycemic HbA1c control (HbA1c ≤ 6.5%) after total pancreatectomy with islet autotransplantation (TP-IAT). Patients who underwent TP-IAT (n = 371) were reviewed for metabolic measures before TP-IAT and for insulin independence and glycemic control at 1, 3, and 5 years after TP-IAT. Insulin independence and goal glycemic control were achieved in 33% and 68% at 1 year, respectively. Although the groups who were insulin independent and dependent overlap substantially on baseline measures, an individual who has abnormal glycemia (prediabetes HbA1c or fasting glucose) or estimated IEQs/kg < 2500 has a very high likelihood of remaining insulin dependent after surgery. In multivariate logistic regression modelling, metabolic measures correctly predicted insulin independence in about 70% of patients at 1, 3, and 5 years after TP-IAT. In conclusion, metabolic testing measures before surgery are highly associated with diabetes outcomes after TP-IAT at a population level and correctly predict outcomes in approximately two out of three patients. These findings may aid in prognostic counseling for chronic pancreatitis patients who are likely to eventually need TP-IAT.


Assuntos
Diabetes Mellitus , Transplante das Ilhotas Pancreáticas , Pancreatite Crônica , Humanos , Pancreatectomia , Pancreatite Crônica/cirurgia , Estudos Retrospectivos , Transplante Autólogo , Resultado do Tratamento
14.
Am J Transplant ; 21(2): 689-702, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32627325

RESUMO

Despite clinical and laboratory screening of potential donors for transmissible disease, unexpected transmission of disease from donor to recipient remains an inherent risk of organ transplantation. The Disease Transmission Advisory Committee (DTAC) was created to review and classify reports of potential disease transmission and use this information to inform national policy and improve patient safety. From January 1, 2008 to December 31, 2017, the DTAC received 2185 reports; 335 (15%) were classified as a proven/probable donor transmission event. Infections were transmitted most commonly (67%), followed by malignancies (29%), and other disease processes (6%). Forty-six percent of recipients receiving organs from a donor that transmitted disease to at least 1 recipient developed a donor-derived disease (DDD). Sixty-seven percent of recipients developed symptoms of DDD within 30 days of transplantation, and all bacterial infections were recognized within 45 days. Graft loss or death occurred in about one third of recipients with DDD, with higher rates associated with malignancy transmission and parasitic and fungal diseases. Unexpected DDD was rare, occurring in 0.18% of all transplant recipients. These findings will help focus future efforts to recognize and prevent DDD.


Assuntos
Doenças Transmissíveis , Transplante de Órgãos , Comitês Consultivos , Doenças Transmissíveis/etiologia , Humanos , Transplante de Órgãos/efeitos adversos , Doadores de Tecidos , Transplantados
15.
Pancreatology ; 21(8): 1491-1497, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34538580

RESUMO

BACKGROUND/OBJECTIVES: The effect of total pancreatectomy with islet autotransplantation (TPIAT) on bone mineral density (BMD) in patients with CP is unknown. We aimed to assess bone health in patients with CP after TPIAT. METHODS: We measured BMD, BMD Z-score, and bone mineral content (BMC) for total body, lumbar spine, right and left hip in 78 patients before and after TPIAT using dual-energy X-ray absorptiometry (DXA, n = 78 pre-TPIAT, n = 65 paired pre- and 12 months post-TPIAT, n = 33 paired 12 and 18 months post-TPIAT), and tested for association with clinical history including age, smoking status, and medications using paired and two-sample t-tests, linear regression, and Fisher's exact test. Laboratory measures related to bone health were also assessed. RESULTS: In the patients with pre-TPIAT DXA, 12% had low BMD (Z-score ≤ -2). BMD, BMD Z-score, and BMC all decreased from pre-to 12 months post-TPIAT. BMD declined by 1.7%-4.1% with the greatest change at the hips. Adjusted for change in lean and fat body mass, DXA changes remained significant for total body and hip. Serum carboxy-terminal collagen crosslinks telopeptide and alkaline phosphatase increased at 12 months post-TPIAT, suggesting possible increased bone remodeling. BMD, BMD Z-score, and BMC did not change between 12 months and 18 months in any of the four regions (p > 0.6). CONCLUSIONS: TPIAT is associated with decreases in BMD in the body, lumbar, and hip regions of patients with CP in the first year after TPIAT but these appear to stabilize between 12 and 18 months after TPIAT.


Assuntos
Densidade Óssea , Pancreatectomia , Humanos , Transplante Autólogo
16.
Pancreatology ; 21(1): 275-281, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33323311

RESUMO

BACKGROUND AND AIMS: Many patients undergoing total pancreatectomy with islet autotransplant (TPIAT) for severe, refractory chronic pancreatitis or recurrent acute pancreatitis have a history of endoscopic retrograde cholangiopancreatography (ERCP). Using data from the multicenter POST (Prospective Observational Study of TPIAT) cohort, we aimed to determine clinical characteristics associated with ERCP and the effect of ERCP on islet yield. METHODS: Using data from 230 participants (11 centers), demographics, pancreatitis history, and imaging features were tested for association with ERCP procedures. Logistic and linear regression were used to assess association of islet yield measures with having any pre-operative ERCPs and with the number of ERCPs, adjusting for confounders. RESULTS: 175 (76%) underwent ERCPs [median number of ERCPs (IQR) 2 (1-4). ERCP was more common in those with obstructed pancreatic duct (p = 0.0009), pancreas divisum (p = 0.0009), prior pancreatic surgery (p = 0.005), and longer disease duration (p = 0.004). A greater number of ERCPs was associated with disease duration (p < 0.0001), obstructed pancreatic duct (p = 0.006), and prior pancreatic surgery (p = 0.006) and increased risk for positive islet culture (p < 0.0001). Mean total IEQ/kg with vs. without prior ERCP were 4145 (95% CI 3621-4669) vs. 3476 (95% CI 2521-4431) respectively (p = 0.23). Adjusting for confounders, islet yield was not significantly associated with prior ERCP, number of ERCPs, biliary or pancreatic sphincterotomy or stent placement. CONCLUSIONS: ERCP did not appear to adversely impact islet yield. When indicated, ERCP need not be withheld to optimize islet yield but the risk-benefit ratio of ERCP should be considered given its potential harms, including risk for excessive delay in TPIAT.


Assuntos
Colangiopancreatografia Retrógrada Endoscópica/métodos , Transplante das Ilhotas Pancreáticas/métodos , Ilhotas Pancreáticas/diagnóstico por imagem , Pancreatectomia/métodos , Adolescente , Adulto , Idoso , Criança , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pancreatopatias/cirurgia , Pancreatite/cirurgia , Estudos Prospectivos , Recidiva , Adulto Jovem
17.
Clin Transplant ; 35(11): e14444, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34318522

RESUMO

BACKGROUND: The Kidney Allocation System (KAS) includes a scoring system to match transplant candidate life expectancy with expected longevity of the donor kidney, and a backdating policy that gives waitlist time credit to patients waitlisted after starting dialysis treatment (post-dialysis). We estimated the effect of the KAS on employment among patient subgroups targeted by the policy. METHODS: We used a sample selection model to compare employment after transplant before and after KAS implementation among patients on the kidney-only transplant waitlist between December 4, 2011 and December 31, 2017. RESULTS: Post-dialysis transplant recipients aged 18-49 were significantly more likely to be employed 1-year post transplant in the post-KAS era compared to the pre-KAS era. Transplant recipients aged 35-64 with no dialysis treatment were significantly less likely to be employed 1 year after transplant in the post-KAS era compared to the pre-KAS era. CONCLUSIONS: This study provides the first assessment of employment after DDKT under the KAS and provides important information about both the methods used to measure employment after transplant and the outcome under the KAS. Changes in employment after DDKT among various patient subgroups have important implications for assessing long-term patient and societal effects of the KAS and organ allocation policy.


Assuntos
Transplante de Rim , Obtenção de Tecidos e Órgãos , Humanos , Rim , Retorno ao Trabalho , Doadores de Tecidos , Transplantados
18.
Transpl Int ; 34(1): 87-96, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33020957

RESUMO

The Igls criteria assess islet function after islet allotransplant, based on C-peptide, insulin use, hemoglobin A1c, and severe hypoglycemia. However, these criteria as currently defined cannot be applied to total pancreatectomy islet autotransplant (TPIAT) patients. We tested modified criteria for assessing islet function in a large cohort of TPIAT patients (n = 379). Metabolic outcomes were assessed. We assigned Auto-Igls class to each patient as able and evaluated the utility, validity, and perioperative risk factors of Auto-Igls at 1-year post-IAT. We tested the association of Auto-Igls with independent measures of islet graft function, specifically continuous glucose monitoring (CGM) data or acute C-peptide response to glucose (ACRglu) from intravenous glucose tolerance tests. An Auto-Igls class was assigned to 264 patients (69%). Among patients who could not be classified, most were missing exact insulin dose. Seventy-three percent of TPIAT recipients were classified as optimal or good at 1 year. The only significant predictor of Auto-Igls class was islet mass transplanted (P < 0.0001). Auto-Igls class was associated with percent time in range (70-140 mg/dl) on CGM (P = 0.02) and ACRglu (P < 0.0001). Modified Igls classification for IAT permits simple, comprehensive assessment of metabolic outcomes after TPIAT and is associated with other islet functional measures.


Assuntos
Transplante das Ilhotas Pancreáticas , Pancreatectomia , Autoenxertos , Glicemia , Automonitorização da Glicemia , Humanos , Estudos Retrospectivos , Transplante Autólogo , Resultado do Tratamento
19.
Transpl Int ; 34(5): 872-881, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33660330

RESUMO

Hepatic steatosis (HS) beyond a certain degree can jeopardize living donor (LD) safety, particularly in right lobe (RL) donors, making it a major obstacle for donor pool expansion in adult-to-adult living donor liver transplantation (ALDLT). From July 2004 to June 2016, 58 LDs donated their RLs despite having moderate HS (30%-50% steatosis) determined by intraoperative biopsy at a single center. We performed greedy matching to compare the outcomes of the donors and recipients of this group with those of LDs with no HS. The mean left lobe (LL) HS value in the 58 cases was 20.9 ± 12.4%, which was significantly lower than the mean RL HS value (38.8 ± 6.7%, P < 0.001). The mean ratio of the remnant LL to the total liver volume was 37.8 ± 2.2. No differences were observed in the postoperative liver function and donor and recipient morbidity and mortality rates. The liver regeneration rates in recipients and donors at 1 month, 6 months, and 1 year postoperatively did not differ significantly. The patient and graft survival rates of the recipients showed no differences. The use of well-selected RL grafts with moderate steatosis does not impair graft function, recipient outcomes, or donor safety.


Assuntos
Fígado Gorduroso , Transplante de Fígado , Adulto , Hepatectomia/efeitos adversos , Humanos , Fígado , Doadores Vivos , Estudos Retrospectivos
20.
Am J Transplant ; 20(9): 2332-2336, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32282992

RESUMO

The novel coronavirus disease 2019 (COVID-19) is impacting transplant programs around the world, and, as the center of the pandemic shifts to the United States, we have to prepare to make decisions about which patients to transplant during times of constrained resources. In this paper, we discuss how to transition from the traditional justice versus utility consideration in organ allocation to a more nuanced allocation scheme based on ethical values that drive decisions in times of absolute scarcity. We recognize that many decisions are made based on the practical limitations that transplant programs face, especially at the extremes. As programs make the transition from a standard approach to a resource-constrained approach to transplantation, we utilize a framework for ethical decisions in settings of absolutely scarce resources to help guide programs in deciding which patients to transplant, which donors to accept, how to minimize risk, and how to ensure the best utilization of transplant team members.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Alocação de Recursos para a Atenção à Saúde/organização & administração , Recursos em Saúde/estatística & dados numéricos , Transplante de Órgãos/estatística & dados numéricos , Pneumonia Viral/epidemiologia , Alocação de Recursos/métodos , COVID-19 , Humanos , Pandemias , Seleção de Pacientes , SARS-CoV-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA